About this course

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that affects millions of people worldwide. If left unmanaged, it may cause organ damage and can lead to life-threatening complications such as cardiovascular diseases as well as diabetic nephropathy, retinopathy, and neuropathy.¹ Maintaining good glycaemic control is crucial to managing T2DM, and dipeptidyl peptidase-4 inhibitors (DPP4is) have emerged as effective antihyperglycaemic agents to help regulate blood glucose levels and mitigate the risk of associated cardiovascular complications.¹^,²^​ Watch this CME-accredited video module to learn more about the role of DPP4is in the management of T2DM.

Learning outcomes

• Understand the prevalence of T2DM in Hong Kong
• Describe the role of glycaemic control in reducing the risk of diabetes-related complications
• Identify the need for treatment escalation
• Gain updated insights from the United Kingdom Prospective Diabetes Study
• Recognise the significance of DPP4is in the management of T2DM

Topics covered

• Incidence of T2DM in Hong Kong
• Trends in drug usage and their impact on glycaemic outcomes
• The importance of glycaemic control in managing T2DM
• Early intervention for the legacy effect: why timely intensive treatment is crucial in the management of T2DM
• The effect of the 3-in-1 strategy on managing T2DM, as seen in the STENO-2 trial
• The benefits of managing T2DM with DPP4is
• The roles of sodium/glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in reducing the risk of major adverse cardiovascular events

References

• Alfroz A, et al. Sci Rep 2019;9:10248.
• Papagianni M, Tziomalos K. Hippokratia 2015;19:195-199.

Organised by: